AMEX:OGEN

Stock Analysis Report

Executive Summary

Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis.

Snowflake

Fundamentals

Excellent balance sheet and fair value.

Risks

  • Oragenics has significant price volatility in the past 3 months.

Share Price & News

How has Oragenics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-10.2%

OGEN

0.6%

US Biotechs

-0.6%

US Market


1 Year Return

-29.8%

OGEN

-11.2%

US Biotechs

0.7%

US Market

OGEN underperformed the Biotechs industry which returned -10.8% over the past year.

OGEN underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

OGENIndustryMarket
7 Day-10.2%0.6%-0.6%
30 Day15.0%2.1%4.9%
90 Day7.0%0.4%1.7%
1 Year-29.8%-29.8%-10.4%-11.2%3.0%0.7%
3 Year-90.5%-90.5%5.9%2.3%44.8%35.4%
5 Year-95.8%-95.8%3.7%-1.3%62.0%44.3%

Price Volatility Vs. Market

How volatile is Oragenics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oragenics undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Oragenics's share price is below the future cash flow value, and at a moderate discount (> 20%).

Oragenics's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Oragenics is loss making, we can't compare its value to the US Biotechs industry average.

Oragenics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Oragenics, we can't assess if its growth is good value.


Price Based on Value of Assets

Oragenics is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Oragenics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

6.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Oragenics is high growth as no revenue estimate data is available.

Oragenics is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare Oragenics's revenue growth to the United States of America market average as no estimate data is available.

Unable to compare Oragenics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Oragenics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Oragenics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Oragenics performed over the past 5 years?

-2.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Oragenics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Oragenics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Oragenics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Oragenics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Oragenics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Oragenics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Oragenics's financial position?


Financial Position Analysis

Oragenics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Oragenics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Oragenics's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (0.3% vs 0.1% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2081.7x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Oragenics has sufficient cash runway for 2.3 years based on current free cash flow.

Unable to confirm if Oragenics has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is Oragenics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Oragenics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Oragenics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Oragenics has not reported any payouts.

Unable to verify if Oragenics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Oragenics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Oragenics's salary, the management and board of directors tenure and is there insider trading?

6.1yrs

Average management tenure


CEO

Alan Joslyn (60yo)

3.3yrs

Tenure

US$834,983

Compensation

Dr. Alan F. Joslyn, Ph.D., has been Chief Executive Officer and President of Oragenics Inc. since June 06, 2016. Dr. Joslyn serves as an Executive-in-Residence at Care Capital, LLC. Dr. Joslyn served as th ...


CEO Compensation Analysis

Alan's remuneration is higher than average for companies of similar size in United States of America.

Alan's compensation has increased whilst company is loss making.


Management Age and Tenure

6.1yrs

Average Tenure

60yo

Average Age

The average tenure for the Oragenics management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

9.3yrs

Average Tenure

66yo

Average Age

The tenure for the Oragenics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Mike Sullivan (63yo)

    CFO, Secretary & Treasurer

    • Tenure: 7.6yrs
    • Compensation: US$505.57k
  • Alan Joslyn (60yo)

    President

    • Tenure: 3.3yrs
    • Compensation: US$834.98k
  • Raman Bedi

    Chairman of International Scientific Advisory Board and Senior Consultant

    • Tenure: 0yrs
  • Martin Handfield (48yo)

    Senior Vice President of Discovery Research

    • Tenure: 4.7yrs
    • Compensation: US$423.15k

Board Members

  • Fred Telling (67yo)

    Chairman

    • Tenure: 8.6yrs
    • Compensation: US$230.35k
  • Alan Dunton (65yo)

    Independent Director

    • Tenure: 8.4yrs
    • Compensation: US$186.60k
  • Per-Erik Saris

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Howard Kuramitsu

    Member of Scientific Advisiory Board

    • Tenure: 0yrs
  • Alan Joslyn (60yo)

    President

    • Tenure: 3.3yrs
    • Compensation: US$834.98k
  • Charlie Pope (67yo)

    Independent Director

    • Tenure: 9.3yrs
    • Compensation: US$199.72k
  • Raman Bedi

    Chairman of International Scientific Advisory Board and Senior Consultant

    • Tenure: 0yrs
  • Hari Parkash

    Member of Scientific Advisory Board

    • Tenure: 13.2yrs
  • Brian Mouatt

    Member of International Scientific Advisory Board

    • Tenure: 13.2yrs
  • Eli Schwarz

    Member of Scientific Advisory Board

    • Tenure: 13.2yrs

Company Information

Oragenics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oragenics, Inc.
  • Ticker: OGEN
  • Exchange: AMEX
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$23.298m
  • Shares outstanding: 46.12m
  • Website: https://www.oragenics.com

Number of Employees


Location

  • Oragenics, Inc.
  • 4902 Eisenhower Boulevard
  • Suite 125
  • Tampa
  • Florida
  • 33634
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OGENAMEX (NYSE MKT LLC)YesCommon StockUSUSDJul 2003
UAVPDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2003

Biography

Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for health ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 23:54
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.